Extended-release naltrexone for treatment of alcohol dependence in primary care

Joshua D. Lee; Ellie Grossman; Danae DiRocco; Andrea Truncali; Kathleen Hanley; David Stevens; John Rotrosen; Marc N. Gourevitch

doi:10.1016/j.jsat.2010.03.005

Extended-release naltrexone for treatment of alcohol dependence in primary care

Joshua D. Lee, Ellie Grossman, Danae DiRocco, Andrea Truncali, Kathleen Hanley, David Stevens, John Rotrosen, Marc N. Gourevitch

Urban Initiative

Research output: Contribution to journal › Article › peer-review

Abstract

The feasibility of using extended-release injectable naltrexone (XR-NTX) to treat alcohol dependence in routine primary care settings is unknown. An open-label, observational cohort study evaluated 3-month treatment retention, patient satisfaction, and alcohol use among alcohol-dependent patients in two urban public hospital medical clinics. Adults seeking treatment were offered monthly medical management (MM) and three XR-NTX injections (380 mg, intramuscular). Physician-delivered MM emphasized alcohol abstinence, medication effects, and accessing mutual help and counseling resources. Seventy-two alcohol-dependent patients were enrolled; 90% (65 of 72) of eligible subjects received the first XR-NTX injection; 75% (49 of 65) initiating treatment received the second XR-NTX injection; 62% (40 of 65), the third. Among the 56% (n = 40) receiving three injections, median drinks per day decreased from 4.1 (95% confidence interval = 2.9-6) at baseline to 0.5 (0-1.7) during Month 3. Extended-release naltrexone delivered in a primary care MM model appears a feasible and acceptable treatment for alcohol dependence.

Original language	English (US)
Pages (from-to)	14-21
Number of pages	8
Journal	Journal of Substance Abuse Treatment
Volume	39
Issue number	1
DOIs	https://doi.org/10.1016/j.jsat.2010.03.005
State	Published - Jul 2010

Keywords

Alcohol medical management
Alcohol pharmacotherapy
Alcohol treatment
Extended-release naltrexone
Primary care

ASJC Scopus subject areas

Phychiatric Mental Health
Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

Access to Document

10.1016/j.jsat.2010.03.005

Cite this

@article{0bd895e098804d37ab27093556c84196,

title = "Extended-release naltrexone for treatment of alcohol dependence in primary care",

abstract = "The feasibility of using extended-release injectable naltrexone (XR-NTX) to treat alcohol dependence in routine primary care settings is unknown. An open-label, observational cohort study evaluated 3-month treatment retention, patient satisfaction, and alcohol use among alcohol-dependent patients in two urban public hospital medical clinics. Adults seeking treatment were offered monthly medical management (MM) and three XR-NTX injections (380 mg, intramuscular). Physician-delivered MM emphasized alcohol abstinence, medication effects, and accessing mutual help and counseling resources. Seventy-two alcohol-dependent patients were enrolled; 90% (65 of 72) of eligible subjects received the first XR-NTX injection; 75% (49 of 65) initiating treatment received the second XR-NTX injection; 62% (40 of 65), the third. Among the 56% (n = 40) receiving three injections, median drinks per day decreased from 4.1 (95% confidence interval = 2.9-6) at baseline to 0.5 (0-1.7) during Month 3. Extended-release naltrexone delivered in a primary care MM model appears a feasible and acceptable treatment for alcohol dependence.",

keywords = "Alcohol medical management, Alcohol pharmacotherapy, Alcohol treatment, Extended-release naltrexone, Primary care",

author = "Lee, {Joshua D.} and Ellie Grossman and Danae DiRocco and Andrea Truncali and Kathleen Hanley and David Stevens and John Rotrosen and Gourevitch, {Marc N.}",

year = "2010",

month = jul,

doi = "10.1016/j.jsat.2010.03.005",

language = "English (US)",

volume = "39",

pages = "14--21",

journal = "Journal of Substance Abuse Treatment",

issn = "0740-5472",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Extended-release naltrexone for treatment of alcohol dependence in primary care

AU - Lee, Joshua D.

AU - Grossman, Ellie

AU - DiRocco, Danae

AU - Truncali, Andrea

AU - Hanley, Kathleen

AU - Stevens, David

AU - Rotrosen, John

AU - Gourevitch, Marc N.

PY - 2010/7

Y1 - 2010/7

N2 - The feasibility of using extended-release injectable naltrexone (XR-NTX) to treat alcohol dependence in routine primary care settings is unknown. An open-label, observational cohort study evaluated 3-month treatment retention, patient satisfaction, and alcohol use among alcohol-dependent patients in two urban public hospital medical clinics. Adults seeking treatment were offered monthly medical management (MM) and three XR-NTX injections (380 mg, intramuscular). Physician-delivered MM emphasized alcohol abstinence, medication effects, and accessing mutual help and counseling resources. Seventy-two alcohol-dependent patients were enrolled; 90% (65 of 72) of eligible subjects received the first XR-NTX injection; 75% (49 of 65) initiating treatment received the second XR-NTX injection; 62% (40 of 65), the third. Among the 56% (n = 40) receiving three injections, median drinks per day decreased from 4.1 (95% confidence interval = 2.9-6) at baseline to 0.5 (0-1.7) during Month 3. Extended-release naltrexone delivered in a primary care MM model appears a feasible and acceptable treatment for alcohol dependence.

AB - The feasibility of using extended-release injectable naltrexone (XR-NTX) to treat alcohol dependence in routine primary care settings is unknown. An open-label, observational cohort study evaluated 3-month treatment retention, patient satisfaction, and alcohol use among alcohol-dependent patients in two urban public hospital medical clinics. Adults seeking treatment were offered monthly medical management (MM) and three XR-NTX injections (380 mg, intramuscular). Physician-delivered MM emphasized alcohol abstinence, medication effects, and accessing mutual help and counseling resources. Seventy-two alcohol-dependent patients were enrolled; 90% (65 of 72) of eligible subjects received the first XR-NTX injection; 75% (49 of 65) initiating treatment received the second XR-NTX injection; 62% (40 of 65), the third. Among the 56% (n = 40) receiving three injections, median drinks per day decreased from 4.1 (95% confidence interval = 2.9-6) at baseline to 0.5 (0-1.7) during Month 3. Extended-release naltrexone delivered in a primary care MM model appears a feasible and acceptable treatment for alcohol dependence.

KW - Alcohol medical management

KW - Alcohol pharmacotherapy

KW - Alcohol treatment

KW - Extended-release naltrexone

KW - Primary care

UR - http://www.scopus.com/inward/record.url?scp=77953620899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953620899&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2010.03.005

DO - 10.1016/j.jsat.2010.03.005

M3 - Article

C2 - 20363090

AN - SCOPUS:77953620899

SN - 0740-5472

VL - 39

SP - 14

EP - 21

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

IS - 1

ER -

Extended-release naltrexone for treatment of alcohol dependence in primary care

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this